Doctor Care Anywhere has revised its market guidance for H1 revenue growth.

Doctor Care Anywhere (ASX: DOC) announced an upgrade in its revenue growth guidance for H1 2024 compared to H1 2023 to a range of 10-15%, up from the previous guidance of 5-10%. This upgrade is due to solid consultation volumes in the period. As presented at the Annual General Meeting on 29th April 2024, the Company has begun restructuring its clinical operations to improve the clinician mix and reduce costs.

Additionally, due to a lack of commercial return, it will be phasing out its AXA Health secondary care pathway, including specialist advice and diagnostics, over the next few months. The Company stated that it is on track to achieve double-digit revenue growth in H1 and is taking the necessary actions to drive profitability and cash generation strategy.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com